In recent years, great success has been achieved on many fronts in the treatment of men with metastatic castration-resistant prostate cancer (CRPC), including novel chemotherapeutics, immunotherapies, bone microenvironment-targeted agents, and hormonal therapies.
Numerous agents are currently in early-phase clinical trial development for the treatment of advanced prostate cancer. These novel therapies target several areas of prostate tumor biology, including the upregulation of androgen signaling and biosynthesis, critical oncogenic intracellular pathways, epigenetic alterations, and cancer immunology. Importantly, the characterization of the prostate cancer genome offers the potential to exploit conserved genetic alterations, which may increase the efficacy of these targeted therapies. Predictive and prognostic biomarkers are urgently needed to maximize therapeutic efficacy and safety of these promising new treatments options in prostate cancer.
Written by:
Clarke JM, Armstrong AJ. Are you the author?
Duke Cancer Institute and the Duke Prostate Center, Department of Medicine, Division of Medical Oncology, Duke University Medical Center, DUMC, Box 102002, Durham, NC, 27710, USA.
Reference: Curr Treat Options Oncol. 2013 Jan 16. Epub ahead of print.
doi: 10.1007/s11864-012-0222-4
PubMed Abstract
PMID: 23322116
